K-RAS –mutated lung adenocarcinomas depend on ERBB signaling, and pan-ERBB inhibitors impair K-RAS–driven lung tumorigenesis.
No takes yet. Share an insight, caveat, or question.
Moll et al. (2018) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: